IRIS
SCHEINER, BERNHARD
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 740
NA - Nord America 685
EU - Europa 538
SA - Sud America 105
AF - Africa 57
Totale 2.125
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 641
RU - Federazione Russa 263
SG - Singapore 257
HK - Hong Kong 133
CN - Cina 129
BR - Brasile 81
VN - Vietnam 60
BD - Bangladesh 56
IT - Italia 54
FR - Francia 44
BJ - Benin 42
DE - Germania 41
GB - Regno Unito 35
AT - Austria 27
IN - India 24
KR - Corea 24
CA - Canada 21
JP - Giappone 18
MX - Messico 15
AR - Argentina 13
IQ - Iraq 10
NL - Olanda 10
PL - Polonia 9
SE - Svezia 9
UA - Ucraina 9
FI - Finlandia 8
ZA - Sudafrica 8
ES - Italia 6
IE - Irlanda 6
LT - Lituania 6
EC - Ecuador 5
CH - Svizzera 4
TR - Turchia 4
AE - Emirati Arabi Uniti 3
CO - Colombia 3
MA - Marocco 3
PH - Filippine 3
TT - Trinidad e Tobago 3
JM - Giamaica 2
NP - Nepal 2
PT - Portogallo 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
TW - Taiwan 2
UY - Uruguay 2
AZ - Azerbaigian 1
BE - Belgio 1
BG - Bulgaria 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
EG - Egitto 1
GE - Georgia 1
HN - Honduras 1
ID - Indonesia 1
IL - Israele 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
PK - Pakistan 1
PS - Palestinian Territory 1
SV - El Salvador 1
TH - Thailandia 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 2.125
Salva come PNG Salva come JPEG
Città #
San Jose 138
Singapore 130
Hong Kong 129
Ashburn 86
Cotonou 42
Los Angeles 40
Council Bluffs 34
Beijing 33
Moscow 29
Santa Clara 26
Lauterbourg 25
Seoul 24
New York 20
Buffalo 18
Falkenstein 16
Ho Chi Minh City 16
Tokyo 16
Vienna 15
São Paulo 14
Orem 13
Hanoi 11
Chicago 10
Clifton 10
Nuremberg 10
Brooklyn 9
Denver 9
London 9
Mexico City 9
Stockholm 9
Warsaw 9
Frankfurt am Main 8
Tianjin 8
Boston 7
Chennai 7
Dublin 7
Helsinki 7
Phoenix 7
Assago 6
Toronto 6
Da Nang 5
Dallas 5
Dhaka 5
Florence 5
Johannesburg 5
Manchester 5
Montreal 5
Poplar 5
Amsterdam 4
Columbus 4
Houston 4
Milan 4
Shenzhen 4
Turin 4
Zurich 4
Ankara 3
Atlanta 3
Baie-D'Urfé 3
Boardman 3
Charlotte 3
Elk Grove Village 3
Honolulu 3
Mumbai 3
Roubaix 3
Secaucus 3
Sorocaba 3
Uberlândia 3
Baghdad 2
Basra 2
Bexley 2
Bologna 2
Calgary 2
Cape Town 2
Chengdu 2
Cleveland 2
Deiva Marina 2
Delhi 2
Guangzhou 2
Guayaquil 2
Haiphong 2
Hangzhou 2
Hải Dương 2
Las Vegas 2
Ludhiana 2
Manassas 2
Manila 2
Medellín 2
Montevideo 2
Najaf 2
Naples 2
New Delhi 2
Newark 2
Ninh Bình 2
Paris 2
Querétaro 2
Quito 2
Raleigh 2
Ryazan 2
Santa Fe 2
Seattle 2
Shanghai 2
Totale 1.194
Salva come PNG Salva come JPEG
Nome #
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 124
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 120
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 106
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 101
Immunotherapy vs Best Supportive Care for Patients with Hepatocellular Cancer with Child-Pugh B Dysfunction 100
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 94
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis 85
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 84
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 81
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors 81
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice 80
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 78
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 77
Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis 76
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213) 74
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram 73
Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy 71
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 69
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 68
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 67
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma 67
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 63
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study 60
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma 58
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden 56
Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy 44
Tumor-infiltrating Neutrophils: Gatekeepers in Liver Cancer Immune Control 41
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 34
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 27
Totale 2.159
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.296
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.296
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202459 16 1 6 1 8 0 8 4 0 1 0 14
2024/2025468 8 0 30 2 6 35 57 60 102 58 22 88
2025/20261.632 64 43 79 165 217 129 234 204 125 136 133 103
Totale 2.159